PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement
December 20, 2024 16:55 ET
|
PharmAla Biotech
PharmAla files audited financials for year ended August 31, 2024, completes continuance and oversubscribed private placement
PharmAla Announces Private Placement
December 13, 2024 09:25 ET
|
PharmAla Biotech
PharmAla announces private placement financing
Psychedelic Science 2025 Conference Announces Workshops, Holiday Sale, and Scholarship Deadline
December 05, 2024 15:44 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
World’s leading psychedelic conference kicks off with workshops from leaders in science, medicine, therapy, policy, Indigenous medicine, and societyUpcoming deadline: speaker submissions, initial...
PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License
November 14, 2024 09:20 ET
|
PharmAla Biotech
PharmAla reaches agreement in principle to trade with a clinical trial to trade its LaNeo MDMA for a data license to the trial outcomes.
PharmAla to supply LaNeo MDMA for Clinical Trial at Yale
November 07, 2024 09:20 ET
|
PharmAla Biotech
PharmAla to supply Yale University with MDMA for clinical trial
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
October 21, 2024 09:25 ET
|
PharmAla Biotech
PharmAla contracted to sell MDMA to Mt. Sinai Hospital, NY. Terminates Contract with CCrest Labs.
PharmAla Launches MDMA Clinical Trial Tool for Researchers
August 22, 2024 09:07 ET
|
PharmAla Biotech
PharmAla announces the launching of a new tool for clinical researchers, and the appointment of a new CFO effective Oct. 1
Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules
May 29, 2024 08:00 ET
|
Optimi Health Corp.
Optimi Health preparing to export 160 doses of MDMA and psilocybin under Australia’s Authorized Prescriber Scheme.
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
May 22, 2024 08:30 ET
|
Optimi Health Corp.
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules
May 14, 2024 08:00 ET
|
Optimi Health Corp.
Optimi Health Receives Certificate of Analysis For GMP MDMA 40mg and 60mg MDMA Capsules.